Rinvoq (upadacitinib) Disease Interactions
There are 8 disease interactions with Rinvoq (upadacitinib):
- Gastrointestinal perforation
- Hepatic impairment
Upadacitinib (applies to Rinvoq) infections
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Tuberculosis -- Latent
Serious and sometimes fatal infections, including opportunistic and reactivation of infections have been reported in patients receiving upadacitinib treatment. It is recommended to avoid the use of upadacitinib in patients with an active, serious infection, including localized infections. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with upadacitinib. Interrupt therapy if a patient develops a new infection or an opportunistic infection and appropriate antimicrobial therapy should be initiated. Treatment with upadacitinib may be resumed once the infection is controlled.
Upadacitinib (applies to Rinvoq) malignancy
Major Potential Hazard, Moderate plausibility. Applicable conditions: History - Skin Cancer, Skin Cancer, Lymphoma, Myeloproliferative Disorder
Malignancies, including non-melanoma skin cancer have been reported with the use of upadacitinib. Consider the risks and benefits of upadacitinib treatment prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer or when considering continuing treatment in patients who develop a malignancy. It is recommended to perform periodic skin examination.
Upadacitinib (applies to Rinvoq) thrombosis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder
Thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated for inflammatory conditions with Janus kinase inhibitors, including upadacitinib. Prior to using this agent in patients who may be at increases risk for thrombosis, it is recommended to consider the risks and benefits associated with treatment. If symptoms of thrombosis occur, patients should be evaluated promptly and treated appropriately.
Upadacitinib (applies to Rinvoq) cytopenias
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
The use of upadacitinib is associated with an increase incidence of neutropenia, lymphopenia, and anemia. Avoid initiation or interrupt treatment with upadacitinib in patients with low neutrophil counts (i.e., ANC less than 1000 cells/mm3), lymphocyte counts (i.e., less than 500 cells/mm3) and low hemoglobin levels (i.e., less than 8 g/dL). It is recommended to evaluate patients for abnormal blood cell counts at baseline and thereafter according to routine patient management.
Upadacitinib (applies to Rinvoq) gastrointestinal perforation
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Diverticula
Gastrointestinal perforation has been reported with the use of upadacitinib. This agent should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs). It is recommended to monitor for new onset abdominal symptoms for early identification of gastrointestinal perforation.
Upadacitinib (applies to Rinvoq) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The use of upadacitinib is not recommended in patients with severe hepatic impairment. No dose adjustment is required in patients with mild or moderate hepatic impairment. Treatment with upadacitinib is associated with increased incidence of liver enzyme elevation. Evaluate baseline liver function and thereafter according to routine patient management. Treatment should be interrupted if drug-induced liver injury is suspected.
Upadacitinib (applies to Rinvoq) hyperlipidemia
Moderate Potential Hazard, Moderate plausibility.
Treatment with upadacitinib is associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Care should be exercised when using this agent in patients with hyperlipidemia. It is recommended to monitor patients after initiation of treatment, and thereafter according to the clinical guidelines and to manage patients accordingly.
Upadacitinib (applies to Rinvoq) vaccination
Moderate Potential Hazard, Moderate plausibility.
Use of live, attenuated vaccines during, or immediately prior to, upadacitinib therapy is not recommended. Prior to initiating treatment with upadacitinib, it is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, in agreement with current immunization guidelines.
Rinvoq (upadacitinib) drug interactions
There are 406 drug interactions with Rinvoq (upadacitinib)
Rinvoq (upadacitinib) alcohol/food interactions
There is 1 alcohol/food interaction with Rinvoq (upadacitinib)
More about Rinvoq (upadacitinib)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 41 Reviews
- Drug class: antirheumatics
- Latest FDA Alerts (1)
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|